Proof-of-concept trial of AmpliPhage-002 for nasal decolonisation of multidrug-resistant Staphylococcus aureus

Trial Profile

Proof-of-concept trial of AmpliPhage-002 for nasal decolonisation of multidrug-resistant Staphylococcus aureus

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs AB SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 09 Jan 2015 New trial record
    • 05 Jan 2015 Instead of initiating this trial, AmpliPhi Biosciences Corporation may initiate a phase I study in patients with topical and wound infections, according to a company media release.
    • 05 Jan 2015 After completion of preclinical studies in 2015, this trial is expected to be initiated at the Walter Reed Institute of Research in the second half of 2015, according to an AmpliPhi Biosciences Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top